Suzhou Therypharm Pharmaceutical, a China-based drug maker, has raised RMB250m ($37m) in its series C round including returning investor Legend Capital, the corporate venturing unit of tech firm Legend.
State-backed SND Ventures Group and investment firm CEC Capital co-led the C round, which also included GP Capital’s Su Shang Fund, Suzhou International Development Venture Capital Holding’s sub-fund, Taihoe Venture Capital, and Honest Capital, according to news provider DealStreetAsia.
Legend Capital and Tenyall Investment had together invested in Therypharm’s undisclosed-size B round in 2018, DealStreetAsia added.
Founded in 2010, Therypharm develops active pharmaceutical ingredients (API) and reagents targeting cancer and cardiovascular diseases.
